ATGGF
Actinogen Medical Limited
Set alert
- YTD
- -26.75%
- 1 year
- +17.20%
- Open
- 0.035
- Prev close
- 0.0293
- Mkt cap
- 113.51M
- Vol
- 10.00K
- Avg vol
- 15.35K
- EPS
- 0.00
- P/E
- 0.00
More statistics
- Low
- 0.035
- High
- 0.035
News
1 week ago proactiveinvestors.com
Actinogen Medical nears key XanaMIA trial readout - ICYMI
Actinogen Medical Ltd (ASX:ACW, OTC:ATGGF) earlier this week highlighted progress towards the November topline readout from its pivotal XanaMIA Phase 2b/3 Alzheimer's disease trial, with the final…
1 week ago proactiveinvestors.com
Actinogen Medical enters ‘database lock' to process XanaMIA' data and confirm findings
The results for Actinogen Medical Ltd (ASX:ACW, OTC:ATGGF)'s latest Alzheimers disease trial, ‘XanaMIA' are set to be released in mid-November. With final patient visits completed, the company…
1 week ago proactiveinvestors.com
Actinogen Medical closes September quarter with XanaMIA readout in sight
Actinogen Medical Ltd (ASX:ACW, OTC:ATGGF) closed the September quarter with its pivotal XanaMIA Phase 2b/3 Alzheimer's disease trial on track for topline results in November and a pro-forma cash…
4 weeks ago proactiveinvestors.com
Actinogen's Xanamem trial hits key milestone ahead of results - ICYMI
Actinogen Medical Ltd (ASX:ACW, OTC:ATGGF) earlier this week completed the final patient visit in its pivotal XanaMIA Phase 2b/3 Alzheimer's disease trial, putting the company on course to report…
1 month ago proactiveinvestors.com
Actinogen Medical completes final XanaMIA patient visit; November Alzheimer's trial results on track
Actinogen Medical Ltd (ASX:ACW, OTC:ATGGF) has completed the final patient visit in its pivotal XanaMIA Phase 2b/3 Alzheimer's disease trial, keeping topline results from the closely watched study on…
2 months ago proactiveinvestors.com
Dow slips, Nasdaq edges lower as August ends in green
4:30pm: Wall Street caps winning month Wall Street closed lower on Monday, but the major indexes still wrapped up a winning August as investors look ahead...
2 months ago proactiveinvestors.com
Nvidia's $12.9bn Hugging Face swoop is really about filling the cloud capacity it has underwritten
The price Nvidia Corp (NASDAQ:NVDA, XETRA:NVD) is reported to be paying is the first thing analysts have flagged, and on the face of it $12.9 billion for...
2 months ago proactiveinvestors.com
UBS says bond market relief from falling yields will not offset deeper structural pressures
UBS has said recent falls in bond yields and oil prices offer only temporary relief, with structural forces likely to keep long-term borrowing costs high,...
2 months ago proactiveinvestors.com
Riot Platforms $9.1B AI deal fuels speculation around Anthropic IPO
Riot Platforms Inc (NASDAQ:RIOT) shares rose about 4% on Tuesday after the bitcoin mining company announced a 20-year data center lease with a leading...
2 months ago proactiveinvestors.com
Traders see little chance of Hormuz shipping recovery by end of August
Prediction market traders have cut the odds of a meaningful recovery in shipping through the Strait of Hormuz by the end of this month, despite renewed talk...
2 months ago proactiveinvestors.com
Hikma jumps 10% as brokers point to profit beat and undemanding rating
Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) shares rose 10% to 1,721p after first-half results came in ahead of expectations on profits, with both Peel...
2 months ago proactiveinvestors.com
Actinogen Medical outlines scientific case for Xanamem in Alzheimer’s disease ahead of pivotal trial results
Actinogen Medical Ltd (ASX:ACW, OTC:ATGGF) has outlined the scientific rationale supporting its lead drug candidate Xanamem® (emestedastat) as a potential...
2 months ago proactiveinvestors.com
The Small Cap Watch: Healthcare, critical minerals and gold explorers advance projects
The S&P/ASX Small Ordinaries Index (ASX) closed at 3,482.30 on Wednesday, August 5, gaining 80.50 points or 2.37%. The index has risen 170.20 points, or...
3 months ago proactiveinvestors.com
Actinogen Medical advances pivotal XanaMIA trial towards November readout - ICYMI
Actinogen Medical Ltd (ASX:ACW, OTC:ATGGF) earlier this week reported continued progress across its clinical, regulatory and financial programs during the...
3 months ago proactiveinvestors.com
Novo Resources expands Wyloo silver targets - ICYMI
Novo Resources Corp (TSX:NVO, OTCQX:NSRPF, ASX:NVO, FRA:1NOR) earlier this week confirmed that maiden reverse circulation drilling at its Wyloo Polymetallic...
3 months ago proactiveinvestors.com
Horizon Gold details A$1.31B Gum Creek NPV - ICYMI
Horizon Gold Ltd (ASX:HRN, OTC:HZGLF, FRA:HO0) earlier this week confirmed a financially robust development pathway for its 100%-owned Gum Creek Gold...
3 months ago proactiveinvestors.com
Resolution Minerals secures second FAST-41 status - ICYMI
Resolution Minerals Ltd (ASX:RML, OTCQB:RLMLF, FRA:NC3) earlier this week secured US Federal FAST-41 Transparency coverage for its Golden Gate tungsten-gold...
3 months ago proactiveinvestors.com
Actinogen Medical’s Xanamem shows meaningful antidepressant activity in Phase 2 trial
Actinogen Medical Ltd (ASX:ACW, OTC:ATGGF) this week reported encouraging evidence that its lead drug candidate Xanamem® (emestedastat) may offer a novel...